ENTX Stock — Entera Bio Ltd.: Cash, EV, Pipeline

What they do

We concentrate on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm. Our pipeline includes differentiated, first-in-class oral peptides targeting PTH(1-34), GLP-1/Glucagon and GLP-2: Currently, most protein therapies are administered via frequent intravenous, subcutaneous or intramuscular injections.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.14

Market cap

$546.1M

Cash

$265.9M

Enterprise value

$280.2M

Balance sheet

Cash	$265.9M
Debt	$0.0M
Net cash	$265.9M
Enterprise value	$280.2M
Basic shares	49.3M shares
Fully diluted shares	84.0M shares
Fully diluted market cap	$263.6M
Cash per share	$5.39
Quarterly burn	$3.5M
Cash runway	3.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

49.3M

Pre-funded warrants

5.4M

Options

9.3M

RSUs

0.1M

Warrants

19.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

84.0M

Cap table as of 2026-06-30.

Price history

Loading ENTX daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

EB613

Phase 2 · Active Modality: oral peptide tablet

Target PTH receptor

Indications

Postmenopausal osteoporosis (Phase 2)

Catalysts

— late 2026

Status note Oral PTH(1-34) tablet (N-Tab platform), 505(b)(2) vs Forteo. FDA accepted plan for single Phase 3 (hip BMD at month 12 primary) to support NDA. Net proceeds of Jul 2026 private placement to fund Phase 3 initiation.

EB612

Preclinical · Active Modality: oral peptide tablet

Target PTH receptor

Partnerships OPKO Biologics: amended collaboration (Feb 2026); 50/50 ownership and development costs

Indications

Hypoparathyroidism (Preclinical)

Status note Once-daily oral long-acting PTH (LA-PTH) analog tablet for hypoparathyroidism; preclinical profile presented Dec 2025 and at ENDO 2026.

EB618

Preclinical · Active Modality: oral peptide tablet

Aliases OXM

Target GLP-1 receptor, glucagon receptor

Partnerships OPKO: collaboration (Mar 2025); 40% Entera / 60% OPKO proceeds and costs, with opt-out provisions

Indications

Obesity / metabolic disorders (Preclinical)

Status note Oral dual GLP-1/glucagon (oxyntomodulin) peptide once-daily tablet (N-Tab platform). Preclinical single-dose NHP PK/PD presented at ENDO 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	2,425,000	+2,425,000	0.11%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ENTX — Entera Bio Ltd. ☆

What they do

Balance sheet

Share structure

Price history

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

ENTX — Entera Bio Ltd.